Jacobs Levy Equity Management
ALXN

Jacobs Levy Equity Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Jacobs Levy Equity Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-56,192
Closed -$6.43M – 1130
2020
Q3 		$6.43M Buy
56,192
+46,137
+459% +$4.98M 0.07% 288
2020
Q2 		$1.13M Buy
+10,055
New +$1.07M 0.01% 645
2017
Q1 		– Sell
-8,240
Closed -$1.01M – 1044
2016
Q4 		$1.01M Buy
+8,240
New +$1.01M 0.02% 552
2015
Q3 		– Sell
-74,266
Closed -$13.4M – 885
2015
Q2 		$13.4M Sell
74,266
-74,543
-50% -$12.9M 0.26% 130
2015
Q1 		$25.8M Buy
148,809
+34,777
+30% +$6.29M 0.44% 65
2014
Q4 		$21.1M Buy
114,032
+8,663
+8% +$1.61M 0.36% 80
2014
Q3 		$17.5M Buy
105,369
+103,437
+5,354% +$17M 0.29% 117
2014
Q2 		$302K Sell
1,932
-188,237
-99% -$29.7M 0.01% 712
2014
Q1 		$28.9M Buy
190,169
+170,879
+886% +$27.2M 0.48% 56
2013
Q4 		$2.56M Sell
19,290
-49,170
-72% -$5.9M 0.04% 390
2013
Q3 		$7.95M Buy
68,460
+50,150
+274% +$5.5M 0.13% 201
2013
Q2 		$1.69M Buy
+18,310
New +$1.76M 0.03% 456

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Jacobs Levy Equity Management's ALXN Position: Q4 2020 in Review

Jacobs Levy Equity Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 56,192 shares — an estimated $6.43M sold.

Jacobs Levy Equity Management first reported a position in ALXN in Q2 2013 and held it in 12 quarters. The position peaked at $28.9M in Q1 2014. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • Jacobs Levy Equity Management reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 56,192 Alexion Pharmaceuticals shares in Q4 2020, an estimated $6.43M.
  • Jacobs Levy Equity Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • Jacobs Levy Equity Management's Alexion Pharmaceuticals position peaked at $28.9M in Q1 2014.
  • 827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2020, filed 16 Feb 2021.